Researchers at the Institute of Biology Leiden (IBL) have developed a new antibiotic, EVG7, which targets the persistent gut bacterium C. difficile, a significant cause of illness, particularly in older adults and immunocompromised individuals. The findings, published in Nature Communications, indicate that EVG7 can effectively combat C. difficile at a much lower dose than existing treatments, significantly reducing the likelihood of infection recurrence—a common issue with current antibiotics.
C. difficile is known for producing toxins that lead to severe gastrointestinal symptoms. Traditional antibiotic therapies, such as vancomycin, often fail to prevent relapses because the bacterium can form resilient spores. The research team, led by Professor Nathaniel Martin and researcher Elma Mons, found that EVG7, designed as an enhanced version of vancomycin, shows promising results in mouse models. Administering a low dose of EVG7 not only treated the infection effectively but also preserved beneficial gut bacteria, particularly from the Lachnospiraceae family, which help inhibit the regrowth of C. difficile.
The study also raises the issue of antibiotic resistance, which can occur with inadequate dosing. However, the researchers believe that EVG7's potency at low doses minimizes this risk. The next step for the team is to secure funding for toxicity studies before moving to human trials, a process that may take several years due to the challenges in attracting investment for antibiotic development, which is often less lucrative than other areas of drug research.
The collaborative research also involved contributions from Leiden University Medical Center and North Carolina State University, highlighting the multidisciplinary effort behind this innovative approach to treating C. difficile infections.